PHL-GEMFIBROZIL 600 MG — DIN 02254867
GEMFIBROZIL : 600 MG · PHARMEL INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is PHL-GEMFIBROZIL?
PHL-GEMFIBROZIL 600 MG contains GEMFIBROZIL : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02254867, held by PHARMEL INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 05-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PHL-GEMFIBROZIL used for?
Adjunct to diet for: very high serum triglycerides (Type IV/V hyperlipidemia) at risk of pancreatitis; hypercholesterolemia and Type IIa/IIb mixed dyslipidemias to regulate lipid levels.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Gemfibrozil cost around the world?
Gemfibrozil is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 1 | 23 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 5 | 7 | EUR███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 2 | EUR███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
42 pack listings across 15 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Gemfibrozil pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Gemfibrozil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Gemfibrozil, across 22 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 1 | TEVA-GEMFIBROZIL | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-GEMFIBROZIL, APO-GEMFIBROZIL CAP 300MG USP | No marketed DIN |
| DOMINION PHARMACAL | 2 | 0 | DOM-GEMFIBROZIL | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-GEMFIBROZIL | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-GEMFIBROZIL CAP 300MG, NU-GEMFIBROZIL TAB 600MG | No marketed DIN |
| OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | 2 | 0 | GEMFIBROZIL CAP 300MG, GEMFIBROZIL TAB 600MG | No marketed DIN |
| PFIZER CANADA ULC | 2 | 0 | LOPID 600MG, LOPID CAP 300MG | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-GEMFIBROZIL | No marketed DIN |
| PHARMEL INC | 2 | 0 | PHL-GEMFIBROZIL | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | GEMFIBROZIL-300 - CAP, GEMFIBROZIL-600 - TAB 600MG | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | RIVA-GEMFIBROZIL | No marketed DIN |
| SCHEIN PHARMACEUTICAL CANADA INC. | 1 | 0 | SCHEINPHARM GEMFIBROZIL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 600 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 300 mg Capsules: HDPE bottles of 100, 250, and 500. 600 mg Tablets: HDPE bottles of 100, 250, and 500. |
| Storage | Store in a dry place at between 15°C and 30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Gemfibrozil |
|---|---|
| ATC code | C10AB04 |
| AHFS class | 84:80.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02254867 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2254867 |
| Brand name | PHL-GEMFIBROZIL |
| Generic / active ingredient | GEMFIBROZIL : 600 MG |
| Market authorization holder | PHARMEL INC |
| Health Canada schedule | Prescription |
| ATC code | C10AB04 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AB |
| Current status | CANCELLED POST MARKET |
| Status date | 05-Apr-2013 |
| Original market date | 2005-02-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended adult dose: 1200 mg daily in two divided doses (600 mg twice daily) 30 minutes before morning and evening meals. Maximum dose: 1500 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hepatic/renal dysfunction; gallbladder disease; hypersensitivity; pregnancy/lactation; Type I hyperlipoproteinemia; concomitant use with repaglinide.
Warnings and precautions
Risk of severe myopathy and rhabdomyolysis, especially with HMG-CoA reductase inhibitors; potential for cholelithiasis (gallstones); liver tumor risk based on animal studies.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-GEMFIBROZIL | 600 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02142074 |
| APO-GEMFIBROZIL | 600 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | 01979582 |
| APO-GEMFIBROZIL CAP 300MG USP | 300 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | 01979574 |
| DOM-GEMFIBROZIL | 600 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | 02230580 |
| DOM-GEMFIBROZIL | 300 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED POST MARKET | 02241608 |
| GEMFIBROZIL CAP 300MG | 300 MG | CAPSULE | OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | 00851922 |
| GEMFIBROZIL TAB 600MG | 600 MG | TABLET | OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | 00851930 |
| GEMFIBROZIL-300 - CAP | 300 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | 02136031 |
| GEMFIBROZIL-600 - TAB 600MG | 600 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | 02136058 |
| LOPID 600MG | 600 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | 00659606 |
2 · Same class — other molecules in ATC C10AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fenofibrate | AA-FENO-MICRO · AA-FENO-SUPER · AVA-FENOFIBRATE MICRO · DOM-FENOFIBRATE MICRO · DOM-FENOFIBRATE SUPRA · FENO-MICRO-200 · FENOFIBRATE · FENOFIBRATE MICRO · FENOFIBRATE-S · FENOMAX · LIPIDIL CAP 100MG · LIPIDIL EZ · LIPIDIL MICRO · LIPIDIL MICRO - CAP 67MG · LIPIDIL SUPRA · LIPIDIL SUPRA 100 MG · MINT-FENOFIBRATE E · MYLAN-FENOFIBRATE MICRO · NOVO-FENOFIBRATE · NOVO-FENOFIBRATE MICRONIZED · NTP-FENOFIBRATE-S · NU-FENO-MICRO · PHL-FENOFIBRATE MICRO · PHL-FENOFIBRATE SUPRA · PMS-FENOFIBRATE · PMS-FENOFIBRATE MICRO · PMS-FENOFIBRATE SUPRA · PRO-FENO-SUPER - 100 · PRO-FENO-SUPER - 160 · Q-FENOFIBRATE MICRO · RAN-FENOFIBRATE S · RATIO-FENOFIBRATE MC · RIVA-FENOFIBRATE MICRO · SANDOZ FENOFIBRATE E · SANDOZ FENOFIBRATE S · SN-FENOFIBRATE E · TEVA-FENOFIBRATE-S | 56 | 10 | Yes |
| Bezafibrate | ACT-BEZAFIBRATE SR · BEZALIP SR · BEZALIP TAB 200MG · JAMP-BEZAFIBRATE SR · PMS-BEZAFIBRATE | 5 | 2 | Yes |
| Gemfibrozil | APO-GEMFIBROZIL · APO-GEMFIBROZIL CAP 300MG USP · DOM-GEMFIBROZIL · GEMFIBROZIL CAP 300MG · GEMFIBROZIL TAB 600MG · GEMFIBROZIL-300 - CAP · GEMFIBROZIL-600 - TAB 600MG · LOPID 600MG · LOPID CAP 300MG · MYLAN-GEMFIBROZIL · NU-GEMFIBROZIL CAP 300MG · NU-GEMFIBROZIL TAB 600MG · PHL-GEMFIBROZIL · PMS-GEMFIBROZIL · RIVA-GEMFIBROZIL · SCHEINPHARM GEMFIBROZIL · TEVA-GEMFIBROZIL | 22 | 1 | Yes |
| Clofibrate | ATROMID S CAP 500MG · ATROMID-S 1GM · ATROMID-S CAP 500MG · NOVO-FIBRATE CAP 500MG | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · Rosuvastatin · Simvastatin | 759 | 286 |
| C10AX | Alirocumab · Dextrothyroxine · Evinacumab · Evolocumab · Ezetimibe · Inclisiran · Lomitapide · Omega-3-Triglycerides Incl. Other Esters And Acids · Omega-3-Triglycerides, Combinations · Probucol | 48 | 28 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PHL-GEMFIBROZIL called?
The same molecule, Gemfibrozil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ausgem | Latin | Australia |
| Lipigem | Latin | Australia |
| LOPID | Latin | Bahrain, Saudi Arabia |
| LOW-LIP | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.